Literature DB >> 17873197

Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach.

Andrew R Haas1, Daniel H Sterman, Ali I Musani.   

Abstract

Malignant pleural effusions (MPEs) are a troublesome and debilitating complication of advanced malignancies, with > 150,000 cases in the United States each year. The standard management approach begins with a diagnostic and/or therapeutic thoracentesis. Should the MPE recur, a more definitive management strategy is often undertaken with several approaches available to the chest physician or surgeon. These options include repeat thoracentesis, tube thoracostomy with chemical pleurodesis, placement of an indwelling cuffed, tunneled pleural catheter with or without pleurodesis, or medical pleuroscopy or video-assisted thoracoscopic surgery with pleurodesis. Each approach has unique advantages, disadvantages, and likelihood of successful symptom relief and pleurodesis. This article will provide a general review of MPE management strategies including information concerning coding, billing, documentation, and a decision approach among these various methods.

Entities:  

Mesh:

Year:  2007        PMID: 17873197     DOI: 10.1378/chest.06-1757

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  Non-intubated video-assisted thoracic surgery as the modality of choice for treatment of recurrent pleural effusions.

Authors:  Solange E Cox; Mark R Katlic
Journal:  Ann Transl Med       Date:  2015-05

Review 2.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

3.  Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters.

Authors:  David E Ost; Carlos A Jimenez; Xiudong Lei; Scott B Cantor; Horiana B Grosu; Donald R Lazarus; Saadia A Faiz; Lara Bashoura; Vickie R Shannon; Dave Balachandran; Lailla Noor; Yousra B Hashmi; Roberto F Casal; Rodolfo C Morice; George A Eapen
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

4.  Sodium hydroxide as a sclerosing agent in patients with neoplastic pleural effusion non-candidates for VATS: results of a minimally invasive protocol.

Authors:  Micaela Raices; Matías E Czerwonko; Agustin Dietrich; Alejandro Da Lozzo; Enrique Beveraggi; David Smith
Journal:  Updates Surg       Date:  2017-08-31

5.  Pleurodesis with povidone-iodine, as an effective procedure in management of patients with malignant pleural effusion.

Authors:  Gholamali Godazandeh; Nasim Haji Qasemi; Mohammad Saghafi; Meisam Mortazian; Pouya Tayebi
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

6.  Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis.

Authors:  Aaron M Olden; Robert Holloway
Journal:  J Palliat Med       Date:  2010-01       Impact factor: 2.947

Review 7.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

Review 8.  Management of malignant pleural effusion.

Authors:  Hongbin Chen; Julie Brahmer
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

9.  Diagnostic value of medical thoracoscopy in malignant pleural effusion induced by non-Hodgkin's lymphoma.

Authors:  Zhen Wang; Yan-Bing Wu; Li-Li Xu; Mu-Lan Jin; Xiao-Li Diao; Xiao-Juan Wang; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  Oncol Lett       Date:  2017-10-19       Impact factor: 2.967

10.  Treatment of malignant pleural effusion: a cost-effectiveness analysis.

Authors:  Varun Puri; Tanya L Pyrdeck; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; Graham A Colditz; G Alexander Patterson; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2012-05-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.